DIRECTOR
Eric Klawiter, MD  Boston, MA

PROGRAM DESCRIPTION
In recent years, the FDA has approved three new oral therapies for relapsing-remitting multiple sclerosis. There are several other treatments for MS that are in the midst of or have completed phase III clinical trials. Additional emerging therapeutics are currently at varying stages of the drug development pipeline. Faculty will discuss the current treatment options, focusing on clinical trial efficacy, side effect profiles, and risk stratification and monitoring. In a case-based interactive format, faculty will discuss how treatment selection is made in individual patients. Additionally, the session will cover treatment of progressive MS.

LEARNING OBJECTIVES
Upon completion, participants should be familiar with new and emerging therapeutics for MS. They should be equipped to improve their management of patients with MS.

RECOMMENDED AUDIENCE
Neurologists and Other Health Care Professionals Responsible for the Diagnosis, Treatment, or Management of Patients with Multiple Sclerosis

SCHEDULE
1:00  Treating Relapsing MS: Choosing Among the Options
      Myla Goldman, MD  Charlottesville, VA

1:45  Treating Relapsing MS: Risk Stratification and Mitigation
      Bruce A. C. Cree, MD, PhD, MCR  San Francisco, CA

2:30  Break

2:45  Is No Evidence of MS Disease Activity an Achievable Goal?
      Robert A. Bermel, MD  Cleveland, OH

3:15  Advances in Understanding and Treating of Progressive MS
      Robert J. Fox, MD, FAAN  Cleveland, OH

Integrated Neuroscience Session: Emerging Therapeutic Advances in Multiple Sclerosis

3 CME
Friday, January 23
1:00 p.m.–4:00 p.m.